[{"id":"50a0dee6-dba1-4ab6-a74f-43429223178c","acronym":"","url":"https://clinicaltrials.gov/study/NCT05976906","created_at":"2023-08-04T17:10:04.308Z","updated_at":"2024-07-02T16:35:40.929Z","phase":"Phase 1","brief_title":"Universal Dual-target NKG2D-NKp44 CAR-T Cells in Advanced Solid Tumors","source_id_and_acronym":"NCT05976906","lead_sponsor":"Zhejiang University","biomarkers":" IL2","pipe":"","alterations":" ","tags":["IL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • CNK-UT"],"overall_status":"Recruiting","enrollment":" Enrollment 36","initiation":"Initiation: 05/23/2023","start_date":" 05/23/2023","primary_txt":" Primary completion: 05/01/2025","primary_completion_date":" 05/01/2025","study_txt":" Completion: 09/01/2025","study_completion_date":" 09/01/2025","last_update_posted":"2023-08-04"},{"id":"6d1193f0-2ca7-4f62-ac97-d72d00f1ac1a","acronym":"","url":"https://clinicaltrials.gov/study/NCT05734898","created_at":"2023-02-21T16:01:41.195Z","updated_at":"2024-07-02T16:35:54.158Z","phase":"","brief_title":"NKG2D CAR-NK \u0026 r/rAML","source_id_and_acronym":"NCT05734898","lead_sponsor":"Zhejiang University","biomarkers":" NKG2D","pipe":"","alterations":" ","tags":["NKG2D"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NKG2D CAR-NK cell therapy"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 03/01/2023","start_date":" 03/01/2023","primary_txt":" Primary completion: 04/01/2024","primary_completion_date":" 04/01/2024","study_txt":" Completion: 09/01/2024","study_completion_date":" 09/01/2024","last_update_posted":"2023-03-03"},{"id":"c89e4f6e-89dc-462f-b9c4-dad107cbf4e2","acronym":"ANGELICA","url":"https://clinicaltrials.gov/study/NCT05302037","created_at":"2022-03-31T18:52:43.718Z","updated_at":"2024-07-02T16:36:14.486Z","phase":"Phase 1","brief_title":"Allogeneic NKG2DL-targeting CAR γδ T Cells (CTM-N2D) in Advanced Cancers","source_id_and_acronym":"NCT05302037 - ANGELICA","lead_sponsor":"CytoMed Therapeutics Pte Ltd","biomarkers":" NKG2D","pipe":"","alterations":" ","tags":["NKG2D"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CTM-N2D"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 9","initiation":"Initiation: 04/01/2022","start_date":" 04/01/2022","primary_txt":" Primary completion: 03/01/2023","primary_completion_date":" 03/01/2023","study_txt":" Completion: 12/01/2023","study_completion_date":" 12/01/2023","last_update_posted":"2022-03-31"},{"id":"19131867-1550-4e69-800e-247cea563505","acronym":"KEYNOTE-B79","url":"https://clinicaltrials.gov/study/NCT04991948","created_at":"2021-08-05T13:53:08.839Z","updated_at":"2025-02-25T16:16:35.370Z","phase":"Phase 1","brief_title":"Study of Pembrolizumab Treatment After CYAD-101 With FOLFOX Preconditioning in Metastatic Colorectal Cancer","source_id_and_acronym":"NCT04991948 - KEYNOTE-B79","lead_sponsor":"Celyad Oncology SA","biomarkers":" MSI","pipe":"","alterations":" ","tags":["MSI"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • 5-fluorouracil • oxaliplatin • leucovorin calcium • CYAD-101"],"overall_status":"Recruiting","enrollment":" Enrollment 34","initiation":"Initiation: 11/22/2021","start_date":" 11/22/2021","primary_txt":" Primary completion: 08/21/2023","primary_completion_date":" 08/21/2023","study_txt":" Completion: 05/25/2038","study_completion_date":" 05/25/2038","last_update_posted":"2022-03-09"}]